Unlike existing CD19 CAR T therapies, AT101 uses a unique epitope located closer to the cell membrane and has demonstrated superior efficacy in preclinical studies. In a study of 12 patients with relapsed or refractory B-cell non-Hodgkin lymphoma, all six patients treated with higher doses of AT101 achieved a complete response without recurrence at 6.5 months.

Remarkably, the therapy showed manageable side effects and has paved the way for potentially innovative advances in cancer treatment. Chief investigator Dr. Marco Ruella expressed his optimism about the findings and underlined the promising potential of the study as it moves into the second phase.

News materials cannot be equated with a doctor’s prescription. Consult an expert before making a decision.

Source: Ferra

Previous articleSwiss banks began to introduce fees on Russians’ blocked assets.
Next articleTele2 will increase communications prices by at least 10%
I am a professional journalist and content creator with extensive experience writing for news websites. I currently work as an author at Gadget Onus, where I specialize in covering hot news topics. My written pieces have been published on some of the biggest media outlets around the world, including The Guardian and BBC News.


Please enter your comment!
Please enter your name here